Trial assesses antibody therapy for chronic active antibody-mediated kidney transplant rejection

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a Phase II trial. Investigators now have data from a Phase III trial with clazakizumab…